An Open-Label, Non-Randomized, Single-Center Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors.

Trial Profile

An Open-Label, Non-Randomized, Single-Center Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2012

At a glance

  • Drugs Eribulin (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Eisai Inc
  • Most Recent Events

    • 22 Dec 2011 Actual patient no 6 added as reported by ClinicalTrials.gov.
    • 05 Jul 2011 Actual end date changed from Sep 2009 to May 2011 as reported by ClinicalTrials.gov.
    • 07 Nov 2009 Actual initiation date changed from May 2009 to Mar 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top